Browse by Medical Category
The Intervention Clinical Trials Program has three primary research objectives:
We research new medications and treatments to treat psychosis (hallucinations, delusions and disorganization), cognition (memory and attention) and negative symptoms (apathy, social withdrawal and loss of emotional expressiveness). The development of new treatments is guided by new findings in genetics and neuroimaging.
We seek to improve existing options through such strategies as combining medication, optimizing dosing and improving compliance.
We have made groundbreaking progress in understanding the mechanisms by which certain antipsychotics cause weight gain and may increase the risk for diabetes. We are looking at experimental alternatives that could prevent these side effects.
We also investigate how certain medications elevate prolactin and the long-term health consequences.
View our most recent publications on PubMed.
David C. Henderson, MD
Oliver Freudenreich, MD
A. Eden Evins, MD, MPH
Corinne Cather, PhD
Daphne Rulf, MD
Christina Borba, PhD, MPH
Oriana Vesga-Lopez, MD
Intervention Clinical Trials Program
Back to Top